Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? [PDF]
Burton E +7 more
europepmc +1 more source
Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars. [PDF]
Mendelsohn AB +5 more
europepmc +1 more source
Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population. [PDF]
DelPrete S +6 more
europepmc +1 more source
Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers - by Provider and Drug dataset. [PDF]
Schedler NC +3 more
europepmc +1 more source
Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same. [PDF]
Park JP, Oh H, Woollett GR.
europepmc +1 more source
Biosimilar Development Considerations for Therapeutic Proteins With Limited Systemic Exposure: A Landscape Analysis and Pathway Evaluation. [PDF]
Wang T +5 more
europepmc +1 more source
Immune-Mediated Inflammatory Diseases: Addressing Safety Concerns and Enhancing the Accessibility of Biosimilars. [PDF]
Feiteira CP, Tavares IC, Ribeiro MHL.
europepmc +1 more source
Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025). [PDF]
Gilbert Farrar K +4 more
europepmc +1 more source
Biosimilars in pemphigus vulgaris
Sharmila Patil +3 more
openaire +3 more sources
The devolution of biosimilars regulations
After two decades of experience with biosimilars, physicochemical and in vitro biological comparison with their reference products appear sufficient to guarantee clinical safety and efficacy. Hence, the regulation of biosimilars has become redundant, and
Doevendans, Erik +4 more
core

